These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7708693)

  • 1. Iontophoresis for modulation of cardiac drug delivery in dogs.
    Labhasetwar V; Underwood T; Schwendeman SP; Levy RJ
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2612-6. PubMed ID: 7708693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iontophoretic transmyocardial drug delivery. A novel approach to antiarrhythmic drug therapy.
    Avitall B; Hare J; Zander G; Bockoff C; Tchou P; Jazayeri M; Akhtar M
    Circulation; 1992 Apr; 85(4):1582-93. PubMed ID: 1555296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model features of a cardiac iontophoretic drug delivery implant.
    Schwendeman SP; Labhasetwar V; Levy RJ
    Pharm Res; 1995 May; 12(5):790-5. PubMed ID: 7479570
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study.
    Gelzer AR; Kraus MS; Rishniw M; Hemsley SA; Moïse NS
    J Vet Cardiol; 2010 Aug; 12(2):93-106. PubMed ID: 20663731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Intravenous Sotalol in Cardiac Arrhythmias.
    Samanta R; Thiagalingam A; Turner C; Lakkireddy DJ; Kovoor P
    Heart Lung Circ; 2018 Nov; 27(11):1318-1326. PubMed ID: 29853342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the efficacy of sotalol and nadolol in the suppression of ventricular ectopic beats.
    Myburgh DP; Smith R; Diamond TH; Faitelson HL; Sommers DK
    S Afr Med J; 1983 Feb; 63(8):263-5. PubMed ID: 6337412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle.
    Gratieri T; Pujol-Bello E; Gelfuso GM; de Souza JG; Lopez RF; Kalia YN
    Eur J Pharm Biopharm; 2014 Feb; 86(2):219-26. PubMed ID: 23791718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sotalol in twenty patients with cardiac arrhythmias.
    Latour Y; Dumont G; Brosseau A; LeLorier J
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):275-8. PubMed ID: 881280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol.
    Fiset C; Drolet B; Hamelin BA; Turgeon J
    J Pharmacol Exp Ther; 1997 Oct; 283(1):148-56. PubMed ID: 9336319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel delivery of antiarrhythmic agents.
    Labhasetwar V; Levy RJ
    Clin Pharmacokinet; 1995 Jul; 29(1):1-5. PubMed ID: 7586894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times.
    Schwendeman SP; Amidon GL; Labhasetwar V; Levy RJ
    J Pharm Sci; 1994 Oct; 83(10):1482-94. PubMed ID: 7884674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapericardial delivery of amiodarone and sotalol: atrial transmural drug distribution and electrophysiological effects.
    Bolderman RW; Hermans JJ; Rademakers LM; Jansen TS; Verheule S; van der Veen FH; Maessen JG
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):355-63. PubMed ID: 19701096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term sotalol therapy in patients with ventricular arrhythmias.
    Mary-Rabine L; Soumagne D; Stiels B
    Acta Cardiol; 1986; 41(2):89-97. PubMed ID: 2424202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotalol: a new class III antiarrhythmic agent.
    Zanetti LA
    Clin Pharm; 1993 Dec; 12(12):883-91. PubMed ID: 8137605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sotalol marketed for life-threatening arrhythmias.
    Clin Pharm; 1993 Mar; 12(3):176. PubMed ID: 8491074
    [No Abstract]   [Full Text] [Related]  

  • 19. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.
    Somberg JC; Preston RA; Ranade V; Molnar J
    Cardiology; 2010; 116(3):219-25. PubMed ID: 20693799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.